October 2008 Volume 26 Number 10, pp 1051 - 1198
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0dXt0EM
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0aAP0EK
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0BRQi0Eq
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0BkE0EK
=====================================================================
The Genome Sequencer FLX System,
powered by 454 Sequencing, enables groundbreaking discoveries in diverse applications, including de novo sequencing, resequencing of whole genomes and target DNA regions,
metagenomics, and RNA analysis.
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0Bony0E5
=====================================================================
=====================================================================
BioFlorida 11th Annual Conference, Amelia Island (10/19-10/21)
Join business and scientific leaders from all sectors of the industry
at Florida's premier bioscience conference.
Speakers: Yank Coble, UNF; James Greenwood, BIO; Bob Ingram, GlaxoSmit
hKline; Stephen Oesterle, Medtronic; John Peyton, Jacksonville Mayor a
nd Ken Pruitt, Florida Senate President.
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B6mu0E3
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0BpT40EW
=====================================================================
=====================================================================
JOHNS HOPKINS UNIVERSITY - Master's Degrees
Earn your MASTER'S degree FULLY ONLINE at Hopkins' Advanced
Biotechnology Studies program. ONLINE Info Session (Nov. 5) for
Bioinformatics, Bioscience Regulatory Affairs, and Biotechnology.
ON-SITE Info Session - Rockville, MD (Oct. 25).
Learn more and RSVP online: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mg0EJ
=====================================================================
----------------------
EDITORIAL
----------------------
Defusing a time bomb p1051
Researchers and their institutions need to dispel a myth about 'independent' research before the media does it for them.
doi:10.1038/nbt1008-1051
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mh0EK
----------------------
NEWS
----------------------
CD20 blockers eye crowded rheumatology market pp1053 - 1054
George S Mack
doi:10.1038/nbt1008-1053
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mi0EL
Roche consolidates grip on anti-angiogenesis market pp1055 - 1056
Nuala Moran
doi:10.1038/nbt1008-1055
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mj0EM
London forges £2 billion research cluster p1056
Nuala Moran
doi:10.1038/nbt1008-1056
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mk0EN
Ark floats gene therapy's boat, for now pp1057 - 1059
Randy Osborne
doi:10.1038/nbt1008-1057
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Ml0EO
Heplisav's topline p1058
Susan Aldridge
doi:10.1038/nbt1008-1058a
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mm0EP
Cloning shop p1058
Hayley Birch
doi:10.1038/nbt1008-1058b
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mn0EQ
FDA to steer nanotech p1060
Jeffrey L Fox
doi:10.1038/nbt1008-1060a
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mo0ER
Plant biotech bonanza p1060
Emily Waltz
doi:10.1038/nbt1008-1060b
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mp0ES
Plasma product companies outmuscle small recombinant players pp1060 - 1061
Peter Mitchell
doi:10.1038/nbt1008-1060c
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mq0ET
Tysabri's troubles return p1061
Hannah Hoag
doi:10.1038/nbt1008-1061
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mr0EU
DATA PAGE
Trends in biotech literature 2007 p1062
Gaspar Taroncher-Oldenburg and Andrew Marshall
doi:10.1038/nbt1008-1062
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Ms0EV
=====================================================================
Are you looking for a partner?
Let us help you select suitable Antibody interaction partners by using
the Attana A100(R) C-Fast system: label-free, molecular interaction analysis in real time.
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0Bpln0Es
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Where to float? pp1063 - 1066
For CEOs of European biotechs who are considering a public exchange, there are a slew of choices. But should they go local or float their company on a foreign trading market?
Nuala Moran
doi:10.1038/bioe.2008.8
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mt0EW
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Ghostbusters should only bust ghosts pp1067 - 1068
Lanie M Adamson, Mary Whitman, Adam Jacobs and Tracy E Bunting-Early
doi:10.1038/nbt1008-1067
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mu0EX
Fuelling the 9 billion pp1068 - 1070
Wayne Martindale and Anthony Trewavas
doi:10.1038/nbt1008-1068
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mv0EY
Allergenicity testing of GM crops pp1070 - 1071
Rob C Aalberse
doi:10.1038/nbt1008-1070
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mw0EZ
Reply to Allergenicity testing of GM crops pp1071 - 1072
doi:10.1038/nbt1008-1071
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mx0Ea
Field-evolved resistance to Bt toxins pp1072 - 1074
Willam Moar et al.
doi:10.1038/nbt1008-1072
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7My0Eb
Field-evolved resistance to Bt toxins pp1074 - 1076
doi:10.1038/nbt1008-1074
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Mz0Ec
COMMENTARY
New therapies from old medicines pp1077 - 1083
Although new botanical drugs pose many challenges for both industry and the FDA, approval of the first botanical prescription drug shows they can be successfully met.
Shaw T Chen et al.
doi:10.1038/nbt1008-1077
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M10EP
BOOK REVIEW
A timely marriage p1084
David McElroy reviews Tomorrow's Table: Organic Farming, Genetics, and the Future of Food by Pamela C Ronald and Raoul W Adamchak
doi:10.1038/nbt1008-1084
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M20EQ
----------------------
FEATURES
----------------------
PATENTS
A nail in the coffin for DNA sequence patents? pp1085 - 1086
Does the recent Board decision in Ex parte Kubin mean the end for biotech patents claiming DNA sequences?
Miles Yamanaka
doi:10.1038/nbt1008-1085
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M30ER
Recent patent applications in proteomics p1087
doi:10.1038/nbt1008-1087
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M40ES
=====================================================================
GWAS Data Analysis & Resequencing GRANT
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B5js0Ew
Open to individuals, academic and non-profit institutions and research
-based organizations worldwide.
GRANT to include:
GWAS Data Analysis
Identification of Regions of Interest
Resequencing Regions of Interest
Resequencing Data
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B5js0Ew
=====================================================================
----------------------
NEWS AND VIEWS
----------------------
Enhancing immunity to HIV through APOBEC pp1089 - 1090
A small molecule that interferes with HIV Vif promotes the antiviral activity of the human protein APOBEC3G.
Reuben Harris
doi:10.1038/nbt1008-1089
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M50ET
From biomarkers to integrated network responses pp1090 - 1092
The ability to quantify carbon fluxes in mammalian cells is a step toward elucidating the dynamic metabolic networks associated with health and disease.
Uwe Sauer and Nicola Zamboni
doi:10.1038/nbt1008-1090
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M60EU
New [beta]-cells from old acini pp1092 - 1093
Pancreatic acinar cells have been reprogrammed in vivo into insulin-expressing cells by adenoviral delivery of three transcription factors.
Michael S German
doi:10.1038/nbt1008-1092
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M70EV
Unveiling viral enablers pp1093 - 1094
Global RNA interference screens uncover the host genes that support infection by HIV, West Nile virus and influenza virus.
Yueh-Ming Loo and Michael Gale, Jr
doi:10.1038/nbt1008-1093
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7M80EW
Research Highlights p1095
doi:10.1038/nbt1008-1095
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NA0Eg
-----------------------------------
FOCUS ON NEXT-GENERATION SEQUENCING
-----------------------------------
----------------------
EDITORIAL
----------------------
Prepare for the deluge p1099
The gobs of data produced by next-generation sequencing are a key problem limiting wider adoption.
doi:10.1038/nbt1008-1099
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NB0Eh
----------------------
NEWS
----------------------
Profile: Rade Drmanac p1100
Launching the world's first commercial human genome sequencing center is currently the 'unreasonable' career ambition of sequencing-by-hybridization pioneer Rade Drmanac.
Laura DeFrancesco
doi:10.1038/nbt1008-1100
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NC0Ei
NEWS FEATURES
Fixing the front end pp1101 - 1104
One bottleneck in next-generation sequencing is genomic sample selection. As research groups tackle the problem, companies are seizing a market opportunity. Ken Garber reports.
Ken Garber
doi:10.1038/nbt1008-1101
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7ND0Ej
What price personal genome exploration? pp1105 - 1108
Companies offering direct-to-consumer genomic information face tough questions about who regulates them, where they fit in health care and how to value their services. What will it take to move them from niche services to a broader customer base? Jeffrey Fox reports.
Jeffrey L Fox
doi:10.1038/nbt1008-1105
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NE0Ek
The sequencing shakeup pp1109 - 1112
Deep sequencing technology could soon be competitive with certain array applications. But the jury remains out on which of the myriad platforms will have the greatest impact and broadest application. Amy Coombs investigates.
Amy Coombs
doi:10.1038/nbt1008-1109
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NF0El
----------------------
OPINION AND COMMENT
----------------------
COMMENTARY
How to get genomes at one ten-thousandth the cost pp1113 - 1115
The NHGRI's Advanced DNA Sequencing Technology program is spearheading the development of platforms that will bring routine whole-genome sequencing closer to reality.
Jeffery A Schloss
doi:10.1038/nbt1008-1113
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NG0Em
----------------------
RESEARCH
----------------------
PERSPECTIVE
The development and impact of 454 sequencing pp1117 - 1124
Jonathan M Rothberg and John H Leamon
doi:10.1038/nbt1485
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NH0En
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NI0Eo
What would you do if you could sequence everything? pp1125 - 1133
Avak Kahvejian, John Quackenbush and John F Thompson
doi:10.1038/nbt1494
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NJ0Ep
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NK0Eq
REVIEWS
Next-generation DNA sequencing pp1135 - 1145
Jay Shendure and Hanlee Ji
doi:10.1038/nbt1486
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NL0Er
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NM0Es
The potential and challenges of nanopore sequencing pp1146 - 1153
Daniel Branton et al.
doi:10.1038/nbt.1495
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NN0Et
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NO0Eu
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PERSPECTIVE
A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology pp1155 - 1160
Markus J Herrgard et al.
doi:10.1038/nbt1492
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NP0Ev
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NQ0Ew
----------------------
RESEARCH
----------------------
ARTICLES
Genome sequencing and analysis of the filamentous fungus Penicillium chrysogenum pp1161 - 1168
Penicillins and derived [beta]-lactam antibiotics are essential in healthcare. To gain more insight into penicillin synthesis van den Berg and colleagues sequence and analyze the genome and transcriptome of the filamentous fungus Penicillium chrysogenum.
Marco A van den Berg et al.
doi:10.1038/nbt.1498
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NR0Ex
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NS0Ey
Notch signaling respecifies the hemangioblast to a cardiac fate pp1169 - 1178
The development of effective methods for generating cardiomyocytes from embryonic stem cells may prove useful in cell replacement therapies and drug screening. Chen et al. show that activation of Notch signaling efficiently converts hematopoietic progenitors derived from mouse embryonic stem cells into cardiovascular progenitors that give rise to large numbers of cardiomyocytes.
Vincent C Chen et al.
doi:10.1038/nbt.1497
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NT0Ez
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NU0E1
Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy pp1179 - 1186
Munger et al. show that infection with human cytomegalovirus upregulates fatty acid biosynthesis and that pharmacological inhibition of this pathway inhibits replication of both this virus and influenza A. This approach, the first to reliably map major carbon fluxes in mammalian cells, extends the promise of metabolomics from diagnostic applications to identification of new therapeutic concepts.
Joshua Munger et al.
doi:10.1038/nbt.1500
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NV0E2
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7AZ0Es
LETTER
Small-molecule inhibition of HIV-1 Vif pp1187 - 1192
The HIV-1 protein Vif, which promotes degradation of the host cell's antiviral APOBEC3 proteins, has yet to be targeted for therapeutic intervention. Nathans et al. use a high-throughput fluorescence screen to identify a small molecule that inhibits HIV replication in cultured cells by antagonizing Vif in an APOBEC3-dependent manner.
Robin Nathans et al.
doi:10.1038/nbt.1496
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NW0E3
Article: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NX0E4
CORRIGENDA
Corrigendum: Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina) p1193
Diego Martinez et al.
doi:10.1038/nbt1008-1193a
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NY0E5
Corrigendum: Public biotech 2007[mdash]the numbers p1193
Stacy Lawrence and Riku Lahteenmaki
doi:10.1038/nbt1008-1193b
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7NZ0E6
Corrigendum: Predicting PDZ domain-peptide interactions from primary sequences p1193
Jiunn R Chen et al.
doi:10.1038/nbt1008-1193c
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Na0EE
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
So you want to be a venture capitalist? pp1195 - 1196
Venture capitalists have a key role in the translation of scientific innovation from idea to commercial reality.
Jason Brown
doi:10.1038/nbt1008-1195
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Nb0EF
PEOPLE
People p1198
doi:10.1038/nbt1008-1198
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B7Nc0EG
=====================================================================
Nature Publishing Group, The University of Miami, and Scripps Florida are pleased to announce:
The Miami 2009 Winter Symposium
Interpreting the Human Genome
January 24-28, 2009
Deauville Beach Resort
Miami Beach, FL, USA
This meeting will showcase these advances in our understanding of human genome regulation and variability as well as the potential of new technologies to drive the advancement of knowledge.
For more information and to register visit: http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0B4mk0Eq
anatureconference
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/en260Xztnp0HjC0Zzu0El
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
